# Axogen to acquire BioCircuit Technologies for $200 million

Axogen, Inc. announced a definitive agreement to acquire BioCircuit Technologies, Inc. for $200 million in cash. The acquisition adds NerveTape, the first FDA-approved device for sutureless peripheral nerve repair, and is expected to close in Q4 2026.

- Type: Acquisition
- Announced: 2026-09-10
- Where: Alachua, Florida; Tampa, Florida, United States
- Value: $200.0M
- Status: announced
- Products: NerveTape sutureless nerve repair device
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Axogen](https://endata.com/companies/94045.md) (acquirer)
- [BioCircuit Technologies](https://endata.com/companies/94046.md) (target)

## Sources

- [ir.axogeninc.com](https://ir.axogeninc.com/news-events/press-releases/detail/1026/axogen-enters-into-definitive-agreement-to-acquire-biocircuit-technologies), 2026-09-10: "Axogen will acquire BioCircuit for total consideration of $200 million in cash at closing."
- [morningstar.com](https://www.morningstar.com/news/globe-newswire/9824358/axogen-enters-into-definitive-agreement-to-acquire-biocircuit-technologies), 2026-09-10: "Transaction expected to be accretive to revenue growth, adjusted EBITDA margin and adjusted EPS in the first year following closing while Axogen remains free cash flow positive."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.